Researchers are developing nanozymes to safely treat inflammation during pregnancy. An international team, including scientists from Empa, ETH Zurich, the Cantonal Hospital of St. Gallen, and Zhejiang University in China, is working on these innovative nanomedicines.
Nanozymes are synthetic particles with enzyme-like properties designed to target inflammation without harming the mother or fetus. Pregnancy complications, such as gestational diabetes and premature birth, are often worsened by inflammation, making effective treatment difficult. The goal is to create nanozymes that can treat inflammatory processes in the placenta safely.
Initial safety studies using human placental tissue models show promising results, indicating that the nanozymes do not disrupt the placental barrier. Further research will evaluate the anti-inflammatory and antibacterial effects of these nanozymes, using a placenta chip to test their impact on early embryonic development. These nanozymes could offer a safer alternative to traditional medications, potentially revolutionizing the treatment of pregnancy complications. The research was published May 20, 2025.